Mga Batayang Estadistika
| LEI | 5299004CC60O9T5HVM83 |
| CIK | 1597264 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Blueprint Medicines Corporation
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| July 29, 2025 |
15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37359 Blueprint Medicines Corporation (Exact name of registrant as |
|
| July 18, 2025 |
SECOND AMENDED AND RESTATED BLUEPRINT MEDICINES CORPORATION (a Delaware corporation) ARTICLE I Exhibit 3.2 SECOND AMENDED AND RESTATED BYLAWS OF BLUEPRINT MEDICINES CORPORATION (a Delaware corporation) ARTICLE I Stockholders SECTION 1. Annual Meetings. The annual meeting of the stockholders of Blueprint Medicines Corporation (the “Corporation”) for the election of directors and for the transaction of such other business as may properly come before the meeting shall be held each year at such |
|
| July 18, 2025 |
As filed with the Securities and Exchange Commission on July 18, 2025 As filed with the Securities and Exchange Commission on July 18, 2025 Registration No. |
|
| July 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 3) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Blueprint Medicines Corporation (Name of Subject Company) Blueprint Medicines Corporation (Name of Person(s) Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securiti |
|
| July 18, 2025 |
As filed with the Securities and Exchange Commission on July 18, 2025 As filed with the Securities and Exchange Commission on July 18, 2025 Registration No. |
|
| July 18, 2025 |
As filed with the Securities and Exchange Commission on July 18, 2025 As filed with the Securities and Exchange Commission on July 18, 2025 Registration No. |
|
| July 18, 2025 |
As filed with the Securities and Exchange Commission on July 18, 2025 S-8 POS As filed with the Securities and Exchange Commission on July 18, 2025 Registration No. |
|
| July 18, 2025 |
Exhibit 99.1 CONTINGENT VALUE RIGHTS AGREEMENT By and between AVENTIS INC. and CONTINENTAL STOCK TRANSFER & TRUST COMPANY as Rights Agent Dated as of July 15, 2025 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.1 Definitions 1 Section 1.2 Additional Definitions 6 Section 1.3 Other Definitional Provisions 7 ARTICLE II CONTINGENT VALUE RIGHTS 7 Section 2.1 CVRs 7 Section 2.2 Nontransferabl |
|
| July 18, 2025 |
As filed with the Securities and Exchange Commission on July 18, 2025 S-8 POS As filed with the Securities and Exchange Commission on July 18, 2025 Registration No. |
|
| July 18, 2025 |
As filed with the Securities and Exchange Commission on July 18, 2025 S-8 POS As filed with the Securities and Exchange Commission on July 18, 2025 Registration No. |
|
| July 18, 2025 |
As filed with the Securities and Exchange Commission on July 18, 2025 S-8 POS As filed with the Securities and Exchange Commission on July 18, 2025 Registration No. |
|
| July 18, 2025 |
As filed with the Securities and Exchange Commission on July 18, 2025 As filed with the Securities and Exchange Commission on July 18, 2025 Registration No. |
|
| July 18, 2025 |
EX-10.1 Exhibit 10.1 [Name] [Date] Dear [Name]: As you know, Blueprint Medicines Corporation, a Delaware corporation. (the “Company”) entered into an Agreement and Plan of Merger, dated as of June 2, 2025, with SANOFI, a French société anonyme (“Parent”), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (“Aventis”), and Rothko Merger Sub, Inc., a Delaware corporation |
|
| July 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) Blueprint Medicines Corporation (Name of Subject Company (Issuer)) ROTHKO MERGER SUB, INC. AVENTIS INC. SANOFI (Names of Filing Persons — Offerors) Common Stock, Par Value $0.001 Per Share (Title of Cl |
|
| July 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 16, 2025 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) (Comm |
|
| July 18, 2025 |
As filed with the Securities and Exchange Commission on July 18, 2025 As filed with the Securities and Exchange Commission on July 18, 2025 Registration No. |
|
| July 18, 2025 |
As filed with the Securities and Exchange Commission on July 18, 2025 As filed with the Securities and Exchange Commission on July 18, 2025 Registration No. |
|
| July 18, 2025 |
SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BLUEPRINT MEDICINES CORPORATION Exhibit 3.1 SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BLUEPRINT MEDICINES CORPORATION FIRST: The name of the Corporation is: Blueprint Medicines Corporation. SECOND: The address of the registered office of the Corporation in the State of Delaware is: 251 Little Falls Drive, in the City of Wilmington, County of New Castle, 19808. The name of its registered agent for service of proc |
|
| July 18, 2025 |
As filed with the Securities and Exchange Commission on July 18, 2025 As filed with the Securities and Exchange Commission on July 18, 2025 Registration No. |
|
| July 18, 2025 |
As filed with the Securities and Exchange Commission on July 18, 2025 POS AM As filed with the Securities and Exchange Commission on July 18, 2025 Registration No. |
|
| July 18, 2025 |
As filed with the Securities and Exchange Commission on July 18, 2025 S-8 POS As filed with the Securities and Exchange Commission on July 18, 2025 Registration No. |
|
| July 18, 2025 |
As filed with the Securities and Exchange Commission on July 18, 2025 As filed with the Securities and Exchange Commission on July 18, 2025 Registration No. |
|
| July 18, 2025 |
As filed with the Securities and Exchange Commission on July 18, 2025 As filed with the Securities and Exchange Commission on July 18, 2025 Registration No. |
|
| July 17, 2025 |
SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 2) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Blueprint Medicines Corporation (Name of Subject Company) Blueprint Medicines Corporation (Name of Person(s) Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class o |
|
| July 17, 2025 |
Sanofi announces extension of Blueprint tender offer EX-99.(a)(5)(I) Exhibit (a)(5)(I) Press Release Sanofi announces extension of Blueprint tender offer Paris, July 17, 2025. Sanofi today announces that Rothko Merger Sub, Inc., a wholly owned subsidiary of Sanofi, has extended the expiration date of its tender offer to purchase all of the outstanding shares of common stock, par value $0.001 per share of Blueprint Medicines Corporation for $129.00 p |
|
| July 17, 2025 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) Blueprint Medicines Corporation (Name of Subject Company (Issuer)) ROTHKO MERGER SUB, INC. AVENTIS INC. SANOFI (Names of Filing Persons — Offerors) Common Stock, Par Value $0.001 Per Share (T |
|
| July 10, 2025 |
SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 1) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Blueprint Medicines Corporation (Name of Subject Company) Blueprint Medicines Corporation (Name of Person(s) Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class o |
|
| July 10, 2025 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) Blueprint Medicines Corporation (Name of Subject Company (Issuer)) ROTHKO MERGER SUB, INC. AVENTIS INC. SANOFI (Names of Filing Persons — Offerors) Common Stock, Par Value $0.001 Per Share (T |
|
| June 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 18, 2025 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) (Comm |
|
| June 17, 2025 |
Exhibit (a)(1)(F) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). |
|
| June 17, 2025 |
Exhibit (d)(5) Execution Version STRICTLY PRIVATE AND CONFIDENTIAL Blueprint Medicines Corporation 38 Sidney Street, Suite 200 Cambridge, MA 02139 United States Attention: Kate Haviland President and Chief Executive Officer May 18, 2025 Re: Project Rothko – Exclusivity Agreement Ladies and Gentlemen: In connection with the consideration by Sanofi of a potential acquisition of Blueprint Medicines C |
|
| June 17, 2025 |
Table of Contents Exhibit (a)(1)(A) Offer To Purchase All Outstanding Shares of Common Stock of BLUEPRINT MEDICINES CORPORATION at $129. |
|
| June 17, 2025 |
Exhibit (a)(1)(E) Notice of Guaranteed Delivery With Respect to the Offer to Purchase All Outstanding Shares of Common Stock of BLUEPRINT MEDICINES CORPORATION at $129. |
|
| June 17, 2025 |
SC 14D9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Blueprint Medicines Corporation (Name of Subject Company) Blueprint Medicines Corporation (Name of Person(s) Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Sec |
|
| June 17, 2025 |
Exhibit (a)(1)(B) LETTER OF TRANSMITTAL To Tender Shares of Common Stock of BLUEPRINT MEDICINES CORPORATION at $129. |
|
| June 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Blueprint Medicines Corporation (Name of Subject Company (Issuer)) ROTHKO MERGER SUB, INC. AVENTIS INC. SANOFI (Names of Filing Persons — Offerors) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) |
|
| June 17, 2025 |
EX-99.(a)(1)(C) Exhibit (a)(1)(C) Offer to Purchase All Outstanding Shares of Common Stock of BLUEPRINT MEDICINES CORPORATION at $129.00 PER SHARE IN CASH, PLUS ONE CONTINGENT VALUE RIGHT PER SHARE REPRESENTING THE RIGHT TO RECEIVE CONTINGENT PAYMENTS OF UP TO AN AGGREGATE AMOUNT OF $6.00 PER SHARE IN CASH UPON THE ACHIEVEMENT OF SPECIFIED MILESTONES ON OR PRIOR TO THE EXPIRATION OF THE APPLICABLE |
|
| June 17, 2025 |
Amendment No. 1 to Confidentiality Agreement Exhibit (d)(3) Amendment No. 1 to Confidentiality Agreement This Amendment No. 1 (this “Amendment”), dated as of November 5, 2024 (“Amendment Effective Date”), between Blueprint Medicines Corporation (“Blueprint”) and SANOFI (“Sanofi”) amends that certain Confidentiality Agreement, dated May 24, 2024, between Sanofi and Blueprint (the “Agreement”). Sanofi and Blueprint are each referred to herein |
|
| June 17, 2025 |
Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of BLUEPRINT MEDICINES CORPORATION at $129. |
|
| June 17, 2025 |
Exhibit (d)(2) CONFIDENTIALITY AGREEMENT This Confidentiality Agreement (the “Agreement”) is made on this 24th day of May, 2024 (the “Effective Date”) by and between: SANOFI, a French corporation, with a principal office at 46, avenue de la Grande Armée, 75017 Paris, France (“Sanofi”), and, BLUEPRINT MEDICINES CORPORATION, a Delaware corporation, with a principal office at 45 Sidney Street, Cambridge, Massachusetts 02139, United States (“Blueprint”). |
|
| June 17, 2025 |
Table 1: Transaction Valuation Calculation of Filing Fee Tables Table 1: Transaction Valuation Transaction Valuation Fee Rate Amount of Filing Fee Fees to be Paid 1 $ 9,570,172,566. |
|
| June 17, 2025 |
Amendment No. 2 to Confidentiality Agreement EX-99.(d)(4) Exhibit (d)(4) Amendment No. 2 to Confidentiality Agreement This Amendment No. 2 (this “Amendment No. 2”), dated as of May 17, 2025 (“Amendment No. 2 Effective Date”), between Blueprint Medicines Corporation (“Blueprint”) and SANOFI (“Sanofi”) amends that certain Confidentiality Agreement, dated May 24, 2024, between Sanofi and Blueprint (the “Agreement”), as amended by Amendment No. |
|
| June 3, 2025 |
Exhibit 99.1 |
|
| June 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Blueprint Medicines Corporation (Name of Subject Company) ROTHKO MERGER SUB, INC. AVENTIS INC. SANOFI (Names of Filing Persons — Offerors) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 09627Y10 |
|
| June 2, 2025 |
Exhibit 99.4 Good morning, This morning, Blueprint announced that we have reached an agreement to be acquired by Sanofi for approximately $9.5 billion, or up to $135 per share in total consideration. Key highlights of the transaction include: · The per share purchase price represents a 33%, 35%, and 49% premium to the company’s current share price, 30– and 60-day volume-weighted average prices as |
|
| June 2, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 2, 2025 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) (Commi |
|
| June 2, 2025 |
Exhibit 99.3 LinkedIn Post: X Post: |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Blueprint Medicines Corporation (Name of Subject Company) ROTHKO MERGER SUB, INC. AVENTIS INC. SANOFI (Names of Filing Persons — Offerors) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 09627Y10 |
|
| June 2, 2025 |
Exhibit 99.1 Press Release Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology · Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio Paris and Cambridge, MA. June 2, 2025. Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly tra |
|
| June 2, 2025 |
Acquisition of Blueprint in rare diseases June 2, 2025 Exhibit 99.4 Acquisition of Blueprint in rare diseases June 2, 2025 Forward-looking statements This communication contains forward-looking statements that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those implied by the forward-looking statements. Forward-looking statements are statements that are not historical facts and may incl |
|
| June 2, 2025 |
Exhibit 99.1 Viva Engage Post from Brian Foard to Message to Specialty Care employees Timing: Monday, June 2, 07:10am CET / 01:10am ET Important Notices regarding Forward Looking Statements and Additional Information for US Shareholders Dear colleagues, Today we signed an agreement to acquire Blueprint Medicines, a global pharmaceutical focused in systemic mastocytosis, a rare immunological diseas |
|
| June 2, 2025 |
CEO email message to Blueprint employees Exhibit 99.1 CEO email message to Blueprint employees E-mail Subject: Blueprint and Sanofi announce combination to accelerate leadership in immunology From: Kate Haviland To: All Blueprint employees and contractors Confidential – Internal Use Only Blue Crew, Since our inception, Blueprint has worked towards our singular mission to alleviate human suffering through innovative and life-changing medi |
|
| June 2, 2025 |
SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Blueprint Medicines Corporation (Name of Subject Company) ROTHKO MERGER SUB, INC. AVENTIS INC. SANOFI (Names of Filing Persons — Offerors) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) |
|
| June 2, 2025 |
Exhibit 99.2 Viva Engage Post from Houman Ashrafian to Sanofi R&D Organization Timing: Monday, June 2, 12:00pm CET / 6:00am ET Important Notices regarding Forward Looking Statements and Additional Information for US Shareholders Dear colleagues, This morning, we announced that we’ve entered into an agreement to acquire Blueprint Medicines, significantly enhancing our position in rare diseases and |
|
| June 2, 2025 |
Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER among SANOFI, AVENTIS INC., ROTHKO MERGER SUB, INC. and BLUEPRINT MEDICINES CORPORATION Dated as of June 2, 2025 TABLE OF CONTENTS Article I THE OFFER 2 Section 1.1 The Offer 2 Section 1.2 Company Actions; Schedule 14D-9 4 Section 1.3 Stockholder Lists 5 Article II THE MERGER 5 Section 2.1 The Merger 5 Section 2.2 Closing; Effective Time 5 |
|
| June 2, 2025 |
Exhibit 99.2 FAQ for blueprint employees About the transaction 1. What is the rationale for the transaction? Blueprint and Sanofi are a strong strategic fit, and we believe this complementary combination will accelerate our mission to deliver life-changing medicines to patients. Blueprint’s portfolio of mast cell targeted therapies fits seamlessly with Sanofi’s global leadership in rare diseases a |
|
| June 2, 2025 |
Blueprint Medicines + Sanofi Overview for the Blue Crew June 2, 2025 Exhibit 99.5 Blueprint Medicines + Sanofi Overview for the Blue Crew June 2, 2025 Blueprint Medicines + Sanofi: a strong strategic fit 2 Well - established global leadership in rare disease and immunology & inflammation Significant resources, infrastructure & capability, and global reach Similar mission and culture centering science and patient impact Leading SM franchise at the intersection of ra |
|
| June 2, 2025 |
Exhibit 99.6 02-Jun-2025 Sanofi (SNY) Investor Relations Call: Acquisition of Blueprint Medicines by Sanofi Thomas: Good morning, everyone. This is Thomas Kudsk Larsen from the Sanofi IR team. Thank you for joining us today to discuss Sanofi’s proposed acquisition of Blueprint Medicines that significantly strengthens our position in rare diseases and which represents a major step forward in our co |
|
| June 2, 2025 |
Exhibit 99.3 X Post LinkedIn Post Additional Information about the Proposed Transaction and Where to Find It The tender offer referred to in this communication has not yet commenced. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell shares, nor is it a substitute for the tender offer materials that Sanofi and its acquis |
|
| June 2, 2025 |
Exhibit 99.1 Press Release Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology • Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio Paris and Cambridge, MA. June 2, 2025. Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly tra |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Blueprint Medicines Corporation (Name of Subject Company) Blueprint Medicines Corporation (Name of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 09627Y109 (CUSIP |
|
| June 2, 2025 |
Exhibit 99.5 |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Blueprint Medicines Corporation (Name of Subject Company) Blueprint Medicines Corporation (Name of Person(s) Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) |
|
| May 1, 2025 |
EXHIBIT 99.1 Blueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance - Achieved 61% year-over-year growth with $149.4 million in AYVAKIT net product revenues in the first quarter 2025 - - Raising AYVAKIT net product revenue guidance to $700 - $720 million for 2025 - - Initiated BLU-808 proof of concept studies in allergic rhinoco |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☑QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-37359 BLUEPRINT MEDICINES CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 26-3632015 (State or Other Jurisdiction of Incorporation or Organization) (I. |
|
| May 1, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported):May 1, 2025 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) (Commiss |
|
| April 24, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ⌧ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ⌧ Defi |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| February 13, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 13, 2025 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) ( |
|
| February 13, 2025 |
As filed with the Securities and Exchange Commission on February 13, 2025 As filed with the Securities and Exchange Commission on February 13, 2025 Registration No. |
|
| February 13, 2025 |
EXHIBIT 99.1 Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results - Achieved $479.0 million in AYVAKIT® (avapritinib) global net product revenues in 2024, including $144.1 million in the fourth quarter - - Anticipate global AYVAKIT net product revenue of approximately $680 million to $710 million in 2025, representing a 45% percent year-over-year growth at the midpoint – - Peak sy |
|
| February 13, 2025 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of the Registrant Entity State/Jurisdiction of Incorporation or Organization Blueprint Medicines Security Corporation Massachusetts Blueprint Medicines (Switzerland) GmbH Switzerland Blueprint Medicines (Netherlands) B.V. Netherlands Blueprint Medicines (UK) Ltd. United Kingdom Blueprint Medicines (Germany) GmbH Germany Blueprint Medicines Spain, S.L. Spain Blueprint Medi |
|
| February 13, 2025 |
Calculation of Filing Fee Tables S-8 Blueprint Medicines Corp Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity 2015 Employee Stock Purchase Plan Common Stock, $0. |
|
| February 13, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37359 BLUEPRINT MEDICINES CORPORATION (Exact name of registrant as specified in its charter) Delaware 26-3632015 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No. |
|
| January 13, 2025 |
Exhibit 99.1 Blueprint Medicines Driving growth and innovation with operational excellence Kate Haviland, Chief Executive Officer J.P. Morgan Healthcare Conference January 13, 2025 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regardin |
|
| January 13, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 13, 2025 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) (C |
|
| December 18, 2024 |
Exhibit 99.1 RLF1 31971120v.1 IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN RE BLUEPRINT MEDICINES CORPORATION ) ) C.A. No. 2024- VERIFIED PETITION FOR RELIEF PURSUANT TO 8 DEL. C. § 205 Petitioner Blueprint Medicines Corporation (“Blueprint” or the “Company”), by and through its undersigned counsel, brings this petition pursuant to 8 Del. C. § 205, seeking to have this Court validate a cor |
|
| December 18, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 13, 2024 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) ( |
|
| October 30, 2024 |
EXHIBIT 99.1 Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance - Achieved $128.2 million in AYVAKIT net product revenues in the third quarter 2024 - - Raising AYVAKIT net product revenue guidance to $475 million to $480 million for 2024 - - On track to initiate the registration-enabling HARBOR Part 2 study of elenestinib in |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☑QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-37359 BLUEPRINT MEDICINES CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 26-3632015 (State or Other Jurisdiction of Incorporation or Organization) (I. |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 30, 2024 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) (C |
|
| August 1, 2024 |
Exhibit 99.1 Blueprint Medicines Reports Second Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance - Achieved $114.1 million in AYVAKIT net product revenues in the second quarter 2024 - - Raising AYVAKIT net product revenue guidance to $435 million to $450 million for 2024 - - Initiated Phase 1 healthy volunteer trial of wild-type KIT inhibitor BLU-808 - CAM |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☑QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-37359 BLUEPRINT MEDICINES CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 26-3632015 (State or Other Jurisdiction of Incorporation or Organization) (I. |
|
| August 1, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 1, 2024 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) (Com |
|
| June 21, 2024 |
Form of award agreements under the Blueprint Medicines Corporation 2024 Stock Incentive Plan Exhibit 99.2 NON-QUALIFIED STOCK OPTION AGREEMENT FOR EMPLOYEES UNDER THE BLUEPRINT MEDICINES CORPORATION 2024 STOCK INCENTIVE PLAN Name of Optionee: %%FIRSTNAME%-% %%LASTNAME%-% No. of Option Shares: %%TOTALSHARESGRANTED,'999,999,999'%-% Option Exercise Price per Share: %%OPTIONPRICE%-% Vesting Start Date: %%VESTBASEDATE%-% Grant Date: %%OPTIONDATE%-% Expiration Date: %%EXPIREDATEPERIOD1%-% Pursu |
|
| June 21, 2024 |
As filed with the Securities and Exchange Commission on June 21, 2024 As filed with the Securities and Exchange Commission on June 21, 2024 Registration No. |
|
| June 21, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Blueprint Medicines Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity 2024 Stock Incentive Plan Common Stock, $0. |
|
| June 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 12, 2024 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) (Comm |
|
| June 14, 2024 |
BLUEPRINT MEDICINES CORPORATION 2024 STOCK INCENTIVE PLAN Exhibit 99.1 BLUEPRINT MEDICINES CORPORATION 2024 STOCK INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Blueprint Medicines Corporation 2024 Stock Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the employees, Non-Employee Directors and Consultants of Blueprint Medicines Corporation (the “Company”) and its Affiliates up |
|
| May 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 22, 2024 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) (Commi |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☑QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-37359 BLUEPRINT MEDICINES CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 26-3632015 (State or Other Jurisdiction of Incorporation or Organization) (I. |
|
| May 2, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 2, 2024 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) (Commis |
|
| May 2, 2024 |
Exhibit 99.1 Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance - Achieved $92.5 million in AYVAKIT net product revenues in the first quarter 2024 - - Raising guidance to $390 million to $410 million in full year AYVAKIT net product revenues - - Strengthening presence in allergy and inflammation with the IND for wild- |
|
| May 2, 2024 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Consent and Termination Agreement This Consent and Termination Agreement (this “Termination Agreement”), dated February 22, 2024, is by and between Royalty Pharma Investments 2019 |
|
| April 25, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 25, 2024 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) (Com |
|
| April 25, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ⌧ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ⌧ Defi |
|
| April 25, 2024 |
Exhibit 99.1 THE POWERFUL MAST CELL a promising target in treating allergic and inflammatory diseases April 25, 2024 Today’s agenda and speakers 2 WELCOME & INTRODUCTION Fouad Namouni, MD President, Research & Development A BLUEPRINT FOR TARGETING MAST CELLS Percy H. Carter, PhD, MBA Chief Scientific Officer MAST CELLS: POWERFUL DRIVERS OF DISEASE Becker Hewes, MD Chief Medical Officer Mariana Cas |
|
| February 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 22, 2024 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) ( |
|
| February 16, 2024 |
As filed with the Securities and Exchange Commission on February 16, 2024 As filed with the Securities and Exchange Commission on February 16, 2024 Registration No. |
|
| February 16, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Blueprint Medicines Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity 2015 Stock Option and Incentive Plan Common Stock, $0. |
|
| February 15, 2024 |
Blueprint Medicines Insider Trading Policy and Special Trading Procedures for Insiders Exhibit 19.1 BLUEPRINT MEDICINES CORPORATION STATEMENT OF COMPANY POLICY ON INSIDER TRADING AND DISCLOSURE A. OVERVIEW Blueprint Medicines Corporation (together with its subsidiaries, the “Company”) designed this Insider Trading Policy (the “Insider Trading Policy”) to prevent the misuse of material nonpublic information and promote compliance by all Company directors, officers and employees with |
|
| February 15, 2024 |
Exhibit 99.1 Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results - Achieved $204.2 million in AYVAKIT®/AYVAKYT® (avapritinib) net product revenues in 2023, including $71.0 million in the fourth quarter - - Anticipate global AYVAKIT net product revenue of approximately $360 million to $390 million in 2024, representing >80 percent year-over-year growth at the midpoint - - Nine pre |
|
| February 15, 2024 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of the Registrant Entity State/Jurisdiction of Incorporation or Organization Blueprint Medicines Security Corporation Massachusetts Blueprint Medicines (Switzerland) GmbH Switzerland Blueprint Medicines (Netherlands) B.V. Netherlands Blueprint Medicines (UK) Ltd. United Kingdom Blueprint Medicines (Germany) GmbH Germany Blueprint Medicines Spain, S.L. Spain Blueprint Medi |
|
| February 15, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 15, 2024 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) ( |
|
| February 15, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37359 BLUEPRINT MEDICINES CORPORATION (Exact name of registrant as specified in its charter) Delaware 26-3632015 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No. |
|
| February 15, 2024 |
Blueprint Medicines Corporation Policy for Recoupment of Erroneously Awarded Compensation Exhibit 97.1 BLUEPRINT MEDICINES CORPORATION POLICY FOR RECOUPMENT OF ERRONEOUSLY AWARDED COMPENSATION I. Overview In accordance with the applicable rules of The Nasdaq Stock Market and the rules issued by the United States Securities and Exchange Commission (the “SEC”) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the Board of Directors (the “Board”) of Blueprint Med |
|
| February 8, 2024 |
SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Blueprint Medicines Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 09627Y109 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the approp |
|
| January 10, 2024 |
BPMC / Blueprint Medicines Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0016-blueprintmedicinescor.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Blueprint Medicines Corp Title of Class of Securities: Common Stock CUSIP Number: 09627Y109 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box t |
|
| January 8, 2024 |
Exhibit 99.1 Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare Conference - AYVAKIT® (avapritinib) launch in indolent systemic mastocytosis to drive strong revenue growth in 2024, with ongoing U.S. launch and recent EU approval - - Expanding mast cell disease leadership with oral wild-type KIT inhibitor, BLU-808, advancing into cli |
|
| January 8, 2024 |
Exhibit 99.2 Making Our Mission a Reality KATE HAVILAND, CHIEF EXECUTIVE OFFICER J.P. MORGAN HEALTHCARE CONFERENCE JANUARY 8, 2024 Adrianne Clinton patient living with systemic mastocytosis Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , as amended, including, without limitation, state |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 8, 2024 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) (Co |
|
| October 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☑QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-37359 BLUEPRINT MEDICINES CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 26-3632015 (State or Other Jurisdiction of Incorporation or Organization) (I. |
|
| October 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 26, 2023 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) (C |
|
| October 26, 2023 |
Exhibit 99.1 Blueprint Medicines Reports Third Quarter 2023 Results - Achieved $54.2 million in AYVAKIT®/AYVAKYT® (avapritinib) net product revenues, representing 90% growth year-over-year, and $56.6 million in total revenues in the third quarter of 2023 – - Approximately 800 patients on AYVAKIT in the U.S. at the end of the third quarter, more than 35% growth in treated patients quarter-over-quar |
|
| August 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 22, 2023 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) (Co |
|
| August 2, 2023 |
Exhibit 10.1 [***] Certain information in this document has been omitted from this exhibit because it (i) is not material and (ii) would be competitively harmful if publicly disclosed. CONFIDENTIAL Amendment No. 1 to Collaboration and License Agreement This Amendment No. 1 (this “Amendment”), dated as of June 5, 2023 (“Amendment Effective Date”), between Blueprint Medicines Corporation (“Blueprint |
|
| August 2, 2023 |
Not for promotional use Second Quarter 2023 Financial Results AUGUST 2, 2023 Exhibit 99.2 Not for promotional use Second Quarter 2023 Financial Results AUGUST 2, 2023 Not for promotional use Agenda 2 INTRODUCTION Kate Haviland Chief Executive Officer AYVAKIT PERFORMANCE Philina Lee, PhD Chief Commercial Officer KEY PORTFOLIO MILESTONES Fouad Namouni, MD President, R&D Q2 2023 FINANCIAL PERFORMANCE Mike Landsittel Chief Financial Officer Not for promotional use Forward - lo |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☑QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-37359 BLUEPRINT MEDICINES CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 26-3632015 (State or Other Jurisdiction of Incorporation or Organization) (I. |
|
| August 2, 2023 |
Exhibit 10.2 [***] Certain information in this document has been omitted from this exhibit because it (i) is not material and (ii) would be competitively harmful if publicly disclosed. CONFIDENTIAL Amendment No. 2 to Collaboration and License Agreement This Amendment No. 2 (this “Amendment”), dated as of July 27, 2023 (“Amendment 2 Effective Date”), between Blueprint Medicines Corporation (“Bluepr |
|
| August 2, 2023 |
Exhibit 99.1 Blueprint Medicines Reports Second Quarter 2023 Results - Achieved $39.9 million in AYVAKIT®/AYVAKYT® (avapritinib) net product revenues and $57.6 million in total revenues in the second quarter of 2023 – - AYVAKIT approved by the FDA for the treatment of adults with indolent systemic mastocytosis on May 22, 2023 - - Announced development candidate BLU-808, an oral, highly potent and |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 2, 2023 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) (Com |
|
| June 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 30, 2023 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) (Comm |
|
| June 27, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 21, 2023 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) (Comm |
|
| May 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 22, 2023 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) (Commi |
|
| May 25, 2023 |
Exhibit 10.1 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. Execution Version FIRST AMENDMENT TO FINANCING AGREEMENT This FIRST AMENDMENT TO FINANCING AGREEMENT (“First Amendment”), dated as of May 22, 2023, is entered into by and among BLUEPRINT MEDICINES CORPORATION, |
|
| May 22, 2023 |
Exhibit 99.1 FDA Approves AYVAKIT® (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis - For the first time, patients with indolent SM have a medicine that treats the primary disease driver and is proven to provide broad and durable symptom relief - - Approval based on the positive PIONEER trial, in which once-daily AYVAKIT achieved significant improvements in disease |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 22, 2023 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) (Commi |
|
| May 4, 2023 |
Exhibit 10.1 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. MUTUAL TERMINATION AGREEMENT This Mutual Termination Agreement (this “Termination Agreement”), effective April 30, 2023 (“Termination Effective Date”), is by and between F. Hoffmann-La Roche Ltd, with an office |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☑QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-37359 BLUEPRINT MEDICINES CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 26-3632015 (State or Other Jurisdiction of Incorporation or Organization) (I. |
|
| May 4, 2023 |
Exhibit 99.1 Blueprint Medicines Reports First Quarter 2023 Results - Achieved $39.1 million in AYVAKIT®/AYVAKYT® (avapritinib) net product revenues and $63.3 million in total revenues in the first quarter of 2023 - - Raising 2023 AYVAKIT net product revenue guidance to $135 million to $145 million for advanced SM and GIST, excluding additional revenue associated with anticipated U.S. FDA approval |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 4, 2023 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) (Commis |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 28, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ⌧ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ⌧ Defi |
|
| March 28, 2023 |
Blueprint Medicines Announces Lift of Partial Clinical Hold on Phase 1/2 VELA Trial of BLU-222 Exhibit 99.1 Blueprint Medicines Announces Lift of Partial Clinical Hold on Phase 1/2 VELA Trial of BLU-222 CAMBRIDGE, Mass., March 28, 2023 – Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the U.S. Food and Drug Administration (FDA) has lifted a partial clinical hold on the Phase 1/2 VELA trial of BLU-222. On February 10, 2023, Blueprint Medicines announced the FDA placed a p |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 28, 2023 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) (Com |
|
| February 27, 2023 |
Exhibit 99.1 AAAAI 2023 ANNUAL MEETING Not for promotional use © 2023 Blueprint Medicines Corporation Suki patient with indolent systemic mastocytosis Detailed data from registrational PIONEER study demonstrate broad impact of AYVAKIT in patients with ISM AAAAI 2023 Annual Meeting February 27, 2023 AAAAI 2023 ANNUAL MEETING Not for promotional use 2 Agenda INTRODUCTION Kate Haviland, Chief Executi |
|
| February 27, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 26, 2023 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) ( |
|
| February 23, 2023 |
Blueprint Medicines to Regain Global Rights to GAVRETO® (pralsetinib) from Roche Exhibit 99.1 Blueprint Medicines to Regain Global Rights to GAVRETO® (pralsetinib) from Roche CAMBRIDGE, Mass., February 23, 2023 – Blueprint Medicines Corporation (NASDAQ: BPMC) today announced it will regain global commercialization and development rights to GAVRETO® (pralsetinib), excluding Greater China, following a decision by Roche to discontinue the collaboration agreement between the compa |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 22, 2023 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) ( |
|
| February 17, 2023 |
As filed with the Securities and Exchange Commission on February 17, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on February 17, 2023 Registration No. |
|
| February 17, 2023 |
between Registrant and one or more Exhibit 4.2 BLUEPRINT MEDICINES CORPORATION Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Subordinated Debt Securities TABLE OF CONTENTS(1) Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trust |
|
| February 17, 2023 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Blueprint Medicines Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Common Stock, par value $0. |
|
| February 17, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Blueprint Medicines Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Common Stock, par value $0. |
|
| February 17, 2023 |
UP TO $300,000,000 COMMON STOCK TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration Statement No.: 333-269843 PROSPECTUS SUPPLEMENT to the Prospectus dated February 17, 2023 UP TO $300,000,000 COMMON STOCK We have entered into a Sales Agreement with Cowen and Company, LLC, or Cowen, relating to shares of our common stock, par value $0.001 per share, offered by this prospectus supplement and the accompanying prospe |
|
| February 17, 2023 |
As filed with the Securities and Exchange Commission on February 17, 2023 S-8 1 tm236850d1s8.htm FORM S-8 As filed with the Securities and Exchange Commission on February 17, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 26-3632015 (State or other jurisdiction |
|
| February 17, 2023 |
Registrant and one or more trustees Exhibit 4.1 BLUEPRINT MEDICINES CORPORATION Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Senior Debt Securities TABLE OF CONTENTS1 Page Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’ |
|
| February 17, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Blueprint Medicines Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity 2015 Stock Option and Incentive Plan Common Stock, $0. |
|
| February 16, 2023 |
Restricted Stock Unit Award for Employees under the 2015 Stock Option and Incentive Plan Exhibit 10.82 RESTRICTED STOCK UNIT AWARD AGREEMENT FOR EMPLOYEES UNDER THE BLUEPRINT MEDICINES CORPORATION 2015 STOCK OPTION AND INCENTIVE PLAN Name of Grantee: %%FIRSTNAME%-% %%LASTNAME%-% No. of Restricted Stock Units: %%TOTALSHARESGRANTED,'999,999,999'%-% Grant Date: %%OPTIONDATE%-% Pursuant to the Blueprint Medicines Corporation 2015 Stock Option and Incentive Plan as amended through the date |
|
| February 16, 2023 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of the Registrant Entity State/Jurisdiction of Incorporation or Organization Blueprint Medicines Security Corporation Massachusetts Blueprint Medicines (Switzerland) GmbH Switzerland Blueprint Medicines (Netherlands) B.V. Netherlands Blueprint Medicines (UK) Ltd. United Kingdom Blueprint Medicines (Germany) GmbH Germany Blueprint Medicines Spain, S.L. Spain Blueprint Medi |
|
| February 16, 2023 |
Exhibit 10.27 THIRD AMENDMENT TO EMPLOYMENT AGREEMENT This Third Amendment to Employment Agreement (this “Third Amendment”) between Blueprint Medicines Corporation, a Delaware corporation (the “Company”), and Chris Murray (the “Executive”), is effective as of January 1, 2023 (the “Third Amendment Effective Date”). Capitalized terms used and not defined herein shall have the meanings ascribed to su |
|
| February 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 16, 2023 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) ( |
|
| February 16, 2023 |
Exhibit 10.81 PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT FOR EMPLOYEES UNDER THE BLUEPRINT MEDICINES CORPORATION 2015 STOCK OPTION AND INCENTIVE PLAN Name of Grantee: Target No. of Performance-Based Restricted Stock Units (“PSUs”): (the “Target Award”) Maximum No. of PSUs:1 Grant Date: Performance Cycle Start Date: Performance Cycle End Date: Pursuant to the Blueprint Medicines Corpor |
|
| February 16, 2023 |
Exhibit 10.79 NON-QUALIFIED STOCK OPTION AGREEMENT FOR NON-EMPLOYEE DIRECTORS UNDER THE BLUEPRINT MEDICINES CORPORATION 2015 STOCK OPTION AND INCENTIVE PLAN Name of Optionee: %%FIRSTNAME%-% %%LASTNAME%-% No. of Option Shares: %%TOTALSHARESGRANTED,'999,999,999'%-% Option Exercise Price per Share: %%OPTIONPRICE%-% Grant Date: %%OPTIONDATE%-% Expiration Date: %%EXPIREDATEPERIOD1%-% Pursuant to the Bl |
|
| February 16, 2023 |
Restricted Stock Unit Award for Employees under the 2020 Incentive Plan Exhibit 10.85 RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE BLUEPRINT MEDICINES CORPORATION 2020 INDUCEMENT PLAN Name of Grantee: %%FIRSTNAME%-% %%LASTNAME%-% No. of Restricted Stock Units: %%TOTALSHARESGRANTED,'999,999,999'%-% Grant Date: %%OPTIONDATE%-% Pursuant to the Blueprint Medicines Corporation 2020 Inducement Plan as amended through the date hereof (the “Plan”), Blueprint Medicines Corp |
|
| February 16, 2023 |
Exhibit 10.77 NON-QUALIFIED STOCK OPTION AGREEMENT FOR EMPLOYEES UNDER THE BLUEPRINT MEDICINES CORPORATION 2015 STOCK OPTION AND INCENTIVE PLAN Name of Optionee: %%FIRSTNAME%-% %%LASTNAME%-% No. of Option Shares: %%TOTALSHARESGRANTED,'999,999,999'%-% Option Exercise Price per Share: %%OPTIONPRICE%-% Vesting Start Date: %%VESTBASEDATE%-% Grant Date: %%OPTIONDATE%-% Expiration Date: %%EXPIREDATEPERI |
|
| February 16, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37359 BLUEPRINT MEDICINES CORPORATION (Exact name of registrant as specified in its charter) Delaware 26-3632015 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No. |
|
| February 16, 2023 |
Exhibit 99.1 Blueprint Medicines Reports Fourth Quarter and Full Year 2022 Results - Achieved $204.0 million in total revenues in 2022, including $111.0 million in AYVAKIT®/AYVAKYT® (avapritinib) net product revenues - - Continued progress toward regulatory approvals of AYVAKIT/AYVAKYT for indolent systemic mastocytosis, with FDA granting priority review of a supplemental new drug application and |
|
| February 16, 2023 |
Exhibit 10.84 RESTRICTED STOCK UNIT AWARD AGREEMENT FOR NON-EMPLOYEE DIRECTORS UNDER THE BLUEPRINT MEDICINES CORPORATION 2015 STOCK OPTION AND INCENTIVE PLAN Name of Grantee: %%FIRSTNAME%-% %%LASTNAME%-% No. of Restricted Stock Units: %%TOTALSHARESGRANTED,'999,999,999'%-% Grant Date: %%OPTIONDATE%-% Pursuant to the Blueprint Medicines Corporation 2015 Stock Option and Incentive Plan as amended thr |
|
| February 16, 2023 |
Exhibit 10.39 THIRD AMENDMENT TO EMPLOYMENT AGREEMENT This Third Amendment to Employment Agreement (this “Third Amendment”) between Blueprint Medicines Corporation, a Delaware corporation (the “Company”), and Ariel Hurley (the “Executive”), is effective as of January 1, 2023 (the “Third Amendment Effective Date”). Capitalized terms used and not defined herein shall have the meanings ascribed to su |
|
| February 16, 2023 |
Exhibit 10.76 NON-QUALIFIED STOCK OPTION AGREEMENT FOR EMPLOYEES UNDER THE BLUEPRINT MEDICINES CORPORATION 2015 STOCK OPTION AND INCENTIVE PLAN Name of Optionee: %%FIRSTNAME%-% %%LASTNAME%-% No. of Option Shares: %%TOTALSHARESGRANTED,'999,999,999'%-% Option Exercise Price per Share: %%OPTIONPRICE%-% Vesting Start Date: %%VESTBASEDATE%-% Grant Date: %%OPTIONDATE%-% Expiration Date: %%EXPIREDATEPERI |
|
| February 16, 2023 |
Exhibit 10.83 RESTRICTED STOCK UNIT AWARD AGREEMENT FOR NON-EMPLOYEE DIRECTORS UNDER THE BLUEPRINT MEDICINES CORPORATION 2015 STOCK OPTION AND INCENTIVE PLAN Name of Grantee: %%FIRSTNAME%-% %%LASTNAME%-% No. of Restricted Stock Units: %%TOTALSHARESGRANTED,'999,999,999'%-% Grant Date: %%OPTIONDATE%-% Pursuant to the Blueprint Medicines Corporation 2015 Stock Option and Incentive Plan as amended thr |
|
| February 16, 2023 |
Exhibit 10.78 NON-QUALIFIED STOCK OPTION AGREEMENT FOR NON-EMPLOYEE DIRECTORS UNDER THE BLUEPRINT MEDICINES CORPORATION 2015 STOCK OPTION AND INCENTIVE PLAN Name of Optionee: %%FIRSTNAME%-% %%LASTNAME%-% No. of Option Shares: %%TOTALSHARESGRANTED,'999,999,999'%-% Option Exercise Price per Share: %%OPTIONPRICE%-% Grant Date: %%OPTIONDATE%-% Expiration Date: %%EXPIREDATEPERIOD1%-% Pursuant to the Bl |
|
| February 16, 2023 |
Non-Qualified Stock Option for Employees under the 2020 Inducement Plan Exhibit 10.80 NON-QUALIFIED STOCK OPTION AGREEMENT UNDER THE BLUEPRINT MEDICINES CORPORATION 2020 INDUCEMENT PLAN Name of Optionee: %%FIRSTNAME%-% %%LASTNAME%-% No. of Option Shares: %%TOTALSHARESGRANTED,'999,999,999'%-% Option Exercise Price per Share: %%OPTIONPRICE%-% Vesting Start Date: %%VESTBASEDATE%-% Grant Date: %%OPTIONDATE%-% Expiration Date: %%EXPIREDATEPERIOD1%-% Pursuant to the Bluepri |
|
| February 16, 2023 |
Fourth Quarter and Full Year 2022 Financial Results FEBRUARY 16, 2023 Exhibit 99.2 Fourth Quarter and Full Year 2022 Financial Results FEBRUARY 16, 2023 Agenda ISM, indolent systemic mastocytosis ; SM, systemic mastocytosis ; AAAAI, American Academy of Allergy, Asthma, and Immunology Annual Conference. 2 Introduction and Notable 2022 Accomplishments Kate Haviland, Chief Executive Officer AYVAKIT Performance and ISM Launch Philina Lee, PhD, Chief Commercial Officer S |
|
| February 10, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 8, 2023 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) (C |
|
| February 10, 2023 |
Blueprint Medicines Announces Partial Clinical Hold for Phase 1/2 VELA Trial of BLU-222 Exhibit 99.1 Blueprint Medicines Announces Partial Clinical Hold for Phase 1/2 VELA Trial of BLU-222 CAMBRIDGE, Mass., February 10, 2023 – Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the U.S. Food and Drug Administration (FDA) verbally informed the company on February 8, 2023 that it has placed a partial clinical hold on the Phase 1/2 VELA trial of BLU-222 due to visual adv |
|
| February 9, 2023 |
BPMC / Blueprint Medicines Corp / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0433-blueprintmedicinescor.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Blueprint Medicines Corp. Title of Class of Securities: Common Stock CUSIP Number: 09627Y109 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box |
|
| February 9, 2023 |
BPMC / Blueprint Medicines Corp / FMR LLC Passive Investment SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.1 BLUEPRINT MEDICINES CORP COMMON STOCK Cusip #09627Y109 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #09627Y109 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 8,926,030 Item 6: 0 Item 7: 8,974,545 Item 8: 0 It |
|
| February 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Blueprint Medicines Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 09627Y109 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w |
|
| January 9, 2023 |
EX-99.1 2 tm232336d2ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Œ © 2023 Blueprint Medicines Corporation KATE HAVILAND, PRESIDENT AND CEO J.P. MORGAN HEALTHCARE CONFERENCE – JANUARY 10, 2023 J.P. MORGAN 2023 Not for promotional use 2 Forward - looking statements This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , as amended, |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 9, 2023 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) (Co |
|
| January 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 6, 2023 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) (Co |
|
| January 6, 2023 |
Blueprint Medicines Appoints John Tsai, M.D. to its Board of Directors EX-99.1 2 tm232336d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Blueprint Medicines Appoints John Tsai, M.D. to its Board of Directors CAMBRIDGE, Mass., (January 6, 2023) / PRNewswire/ - Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of John Tsai, M.D., to its board of directors. Dr. Tsai, who was President, Global Drug Development and Chief Medical Officer at Novartis AG |
|
| December 27, 2022 |
EX-10.1 2 tm2233493d1ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 EXECUTION COPY CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (this “Agreement”), made effective as of the 1st day of January, 2023 (the “Effective Date”), is entered into by and between Blueprint Medicines Corporation, a Delaware corporation (the “Company”), and Jeffrey W. Albers (the “Consultant”). INTRODUCTION WHEREAS, the Consultant is |
|
| December 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 23, 2022 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) ( |
|
| December 27, 2022 |
EX-10.2 3 tm2233493d1ex10-2.htm EXHIBIT 10.2 Exhibit 10.2 EXECUTION COPY AMENDMENT AGREEMENT THIS AMENDMENT AGREEMENT (this “Agreement”), made effective as of the 23rd day of December, 2022 (the “Effective Date”), is entered into by and between Blueprint Medicines Corporation, a Delaware corporation (the “Company”), and Jeffrey W. Albers. INTRODUCTION WHEREAS, Mr. Albers is a member of the Board o |
|
| December 6, 2022 |
Amended and Restated Bylaws, as amended on November 30, 2022, of the Registrant Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF BLUEPRINT MEDICINES CORPORATION (the “Corporation”) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States which is fixed by the Corporation’s Board of Directors (the “Board |
|
| December 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 6, 2022 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) (C |
|
| November 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☑QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-37359 BLUEPRINT MEDICINES CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 26-3632015 (State or Other Jurisdiction of Incorporation or Organization) (I. |
|
| November 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 1, 2022 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) (C |
|
| November 1, 2022 |
Exhibit 99.1 Blueprint Medicines Outlines 2027 Blueprint to Achieve Precision Medicine at Scale and Reports Third Quarter 2022 Financial Results at Investor Day 2022 - On track to submit supplemental new drug application for AYVAKIT® (avapritinib) in non-advanced SM in Q4 2022, with an anticipated U.S. launch in mid-2023 - - Reports updated data from the SYMPHONY trial of BLU-945 demonstrating cli |
|
| November 1, 2022 |
Exhibit 99.2 ™ © 2022 Blueprint Medicines Corporation JIM BAKER SVP, Corporate Affairs INVESTOR DAY 2022 Not for promotional use Our speakers today 3 KATE HAVILAND Chief Executive Officer CHRISTY ROSSI Chief Operating Officer PHILINA LEE, PHD Chief Commercial Officer BECKER HEWES, MD Chief Medical Officer FOUAD NAMOUNI, MD President, R&D PERCY CARTER, PHD Chief Scientific Officer INVESTOR DAY 2022 |
|
| September 23, 2022 |
Exhibit 10.8 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT This Second Amendment to Employment Agreement (this ?Second Amendment?) is dated as of September 23, 2022 (the ?Second Amendment Effective Date?), between Blueprint Medicines Corporation, a Delaware corporation (the ?Company?), and Percy Carter Ph. D., MBA (the ?Executive?). Capitalized terms used and not defined herein shall have the meanings |
|
| September 23, 2022 |
Exhibit 10.7 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT This Second Amendment to Employment Agreement (this ?Second Amendment?) is dated as of September 23, 2022 (the ?Second Amendment Effective Date?), between Blueprint Medicines Corporation, a Delaware corporation (the ?Company?), and Chris Murray (the ?Executive?). Capitalized terms used and not defined herein shall have the meanings ascribed to |
|
| September 23, 2022 |
Exhibit 10.4 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT This Second Amendment to Employment Agreement (this ?Second Amendment?) is dated as of September 23, 2022 (the ?Second Amendment Effective Date?), between Blueprint Medicines Corporation, a Delaware corporation (the ?Company?), and Fouad Namouni, M.D. (the ?Executive?). Capitalized terms used and not defined herein shall have the meanings ascri |
|
| September 23, 2022 |
Exhibit 10.11 FIRST AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT This First Amendment to Amended and Restated Employment Agreement (this ?First Amendment?) is dated as of September 23, 2022 (the ?First Amendment Effective Date?), between Blueprint Medicines Corporation, a Delaware corporation (the ?Company?), and Philina Lee (the ?Executive?). Capitalized terms used and not defined herei |
|
| September 23, 2022 |
Exhibit 10.9 THIRD AMENDMENT TO EMPLOYMENT AGREEMENT This Third Amendment to Employment Agreement (this ?Third Amendment?) is dated as of September 23, 2022 (the ?Third Amendment Effective Date?), between Blueprint Medicines Corporation, a Delaware corporation (the ?Company?), and Debra Durso-Bumpus (the ?Executive?). Capitalized terms used and not defined herein shall have the meanings ascribed t |
|
| September 23, 2022 |
Exhibit 10.2 THIRD AMENDMENT TO EMPLOYMENT AGREEMENT This Third Amendment to Employment Agreement (this ?Third Amendment?) is dated as of September 23, 2022 (the ?Third Amendment Effective Date?), between Blueprint Medicines Corporation, a Delaware corporation (the ?Company?), and Michael Landsittel (the ?Executive?). Capitalized terms used and not defined herein shall have the meanings ascribed t |
|
| September 23, 2022 |
Exhibit 10.10 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT This Second Amendment to Employment Agreement (this ?Second Amendment?) is dated as of September 23, 2022 (the ?Second Amendment Effective Date?), between Blueprint Medicines Corporation, a Delaware corporation (the ?Company?), and Ariel Hurley (the ?Executive?). Capitalized terms used and not defined herein shall have the meanings ascribed to |
|
| September 23, 2022 |
Exhibit 10.6 SECOND AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Second Amendment to Amended and Restated Employment Agreement (this ?Second Amendment?) is dated as of September 23, 2022 (the ?Second Amendment Effective Date?), between Blueprint Medicines Corporation, a Delaware corporation (the ?Company?), and L. Becker Hewes, M.D. (the ?Executive?). Capitalized terms used and not |
|
| September 23, 2022 |
Exhibit 10.5 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT This Second Amendment to Employment Agreement (this ?Second Amendment?) is dated as of September 23, 2022 (the ?Second Amendment Effective Date?), between Blueprint Medicines Corporation, a Delaware corporation (the ?Company?), and Tracey McCain (the ?Executive?). Capitalized terms used and not defined herein shall have the meanings ascribed to |
|
| September 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 23, 2022 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) |
|
| September 23, 2022 |
EX-10.1 2 tm2226591d1ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 FIRST AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT This First Amendment to Amended and Restated Employment Agreement (this “First Amendment”) is dated as of September 23, 2022 (the “First Amendment Effective Date”), between Blueprint Medicines Corporation, a Delaware corporation (the “Company”), and Kathryn Haviland (the “Executiv |
|
| September 23, 2022 |
Exhibit 10.3 FIRST AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT This First Amendment to Amended and Restated Employment Agreement (the ?First Amendment?) is dated as of September 23, 2022 (the ?First Amendment Effective Date?), between Blueprint Medicines Corporation, a Delaware corporation (the ?Company?), and Christina Rossi (the ?Executive?). Capitalized terms used and not defined her |
|
| September 7, 2022 |
Exhibit 99.1 BLUEPRINT MEDICINES COMPANY OVERVIEW SEPTEMBER 2022 Kristine G. Systemic mastocytosis patient ? 2022 Blueprint Medicines Corporation Pioneering the Science of Time Not for promotional use. Forward - looking statements 2 This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , as amended, including, without lim |
|
| September 7, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 7, 2022 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) ( |
|
| August 17, 2022 |
Exhibit 99.2 ? 2022 Blueprint Medicines Corporation R.S., living with systemic mastocytosis PIONEER Part 2 Top-line Results AYVAKIT? (avapritinib) in Non-Advanced Systemic Mastocytosis August 17, 2022 Blueprint Medicines call participants 2 Introduction Kate Haviland, Chief Executive Officer Positive PIONEER Part 2 Topline Results Becker Hewes, MD, Chief Medical Officer Investigator Commentary Mar |
|
| August 17, 2022 |
Exhibit 99.1 Blueprint Medicines Announces Positive Top-line Results from PIONEER Trial of AYVAKIT? (avapritinib) in Patients with Non-Advanced Systemic Mastocytosis Achieving Primary and All Key Secondary Endpoints - AYVAKIT showed a superior mean change in total symptom score (p=0.003), compared to placebo plus best available care - - Highly significant reductions across all objective measures o |
|
| August 17, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 17, 2022 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) (Co |
|
| August 2, 2022 |
Exhibit 99.1 Blueprint Medicines Reports Second Quarter 2022 Results - Achieved $36.5 million in total revenues, including $28.5 million in AYVAKIT? (avapritinib) net product revenues representing 20 percent AYVAKIT revenue growth from Q1 2022 ? - Plan to report topline data for registration-enabling PIONEER trial of AYVAKIT in non-advanced SM in August 2022 - - Licensed KIT exon 13 inhibitor to I |
|
| August 2, 2022 |
Exhibit 10.1 CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(b)(10)(iv). SUCH EXCLUDED INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. PURCHASE AND SALE AGREEMENT dated as of June 30, 2022 between BLUEPRINT MEDICINES CORPORATION and ROYALTY PHARMA INVESTMENTS 2019 ICAV ARTICLE I DEFINED |
|
| August 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☑QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-37359 BLUEPRINT MEDICINES CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 26-3632015 (State or Other Jurisdiction of Incorporation or Organization) (I. |
|
| August 2, 2022 |
As filed with the Securities and Exchange Commission on August 2, 2022 As filed with the Securities and Exchange Commission on August 2, 2022 Registration No. |
|
| August 2, 2022 |
EX-FILING FEES Calculation of Filing Fee Tables Form S-8 (Form Type) Blueprint Medicines Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Amended and Restated 2020 Inducement Plan Common Stock, $0. |
|
| August 2, 2022 |
Exhibit 10.3 CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(b)(10)(iv). SUCH EXCLUDED INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. FINANCING AGREEMENT dated as of June 30, 2022 among BLUEPRINT MEDICINES CORPORATION, as Borrower, CERTAIN SUBSIDIARIES OF BORROWER, as Guarantors, VARIO |
|
| August 2, 2022 |
Exhibit 10.2 CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(b)(10)(iv). SUCH EXCLUDED INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. PURCHASE AND SALE AGREEMENT BY AND AMONG BLUEPRINT MEDICINES CORPORATION, GARNICH ADJACENT INVESTMENTS S.A.R.L. THE VARIOUS OTHER PURCHASERS FROM TIME T |
|
| August 2, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 2, 2022 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) (Com |
|
| June 30, 2022 |
Exhibit 99.1 Blueprint Medicines Announces Transformative $1.25 Billion Strategic Financing Collaborations with Sixth Street and Royalty Pharma ? Strengthens balance sheet with significant non-dilutive, low-cost capital ? Expands ability to bring the promise of precision therapy to broad patient populations through internal R&D and strategic business development ? Propelled by global launches of A |
|
| June 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 30, 2022 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) (Comm |
|
| June 30, 2022 |
Exhibit 99.2 Transformative Strategic Financing Collaboration With Sixth Street and Royalty Pharma June 30, 2022 Cyndi N. Systemic mastocytosis patient ? 2022 Blueprint Medicines Corporation Blueprint Medicines call participants 2 Introduction Kate Haviland , Chief Executive Officer Transaction Overview Mike Landsittel , Chief Financial Officer Q&A All PREPARED REMARKS Not for promotional use. For |
|
| June 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 21, 2022 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) (Comm |
|
| June 27, 2022 |
Amended and Restated 2020 Inducement Plan Exhibit 10.1 BLUEPRINT MEDICINES CORPORATION AMENDED AND RESTATED 2020 INDUCEMENT PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Blueprint Medicines Corporation Amended and Restated 2020 Inducement Plan (the ?Plan?). The purpose of the Plan is to enable Blueprint Medicines Corporation (the ?Company?) and its Subsidiaries to grant equity awards to induce highly |
|
| June 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 23, 2022 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) (Comm |
|
| June 23, 2022 |
Blueprint Medicines Appoints Habib Dable to its Board of Directors Exhibit 99.1 Blueprint Medicines Appoints Habib Dable to its Board of Directors CAMBRIDGE, Mass., (June 23, 2022) / PRNewswire/ - Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of Habib Dable to its board of directors. Mr. Dable, who was Chief Executive Officer of Acceleron Pharma from 2016 to 2021, brings nearly 30 years of experience in strategic leadership, comme |
|
| June 9, 2022 |
Exhibit 99.1 JEFFERIES HEALTHCARE CONFERENCE JUNE 9, 2022 Kristine G. Systemic mastocytosis patient Pioneering the Science of Time Not for promotional use. Forward-looking statements 2 Not for promotional use. This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regard |
|
| June 9, 2022 |
Exhibit 99.2 Blueprint Medicines Reports Continued Progress Toward Goal of Transforming Treatment of Systemic Mastocytosis - New analyses showing AYVAKIT? (avapritinib) significantly improved overall survival in advanced SM, when indirectly compared to real-world data for prior standard therapies, to be presented at EHA 2022 Congress - - Primary endpoint of PIONEER trial of AYVAKIT in non-advanced |
|
| June 9, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 9, 2022 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) (Commi |
|
| May 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 3, 2022 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) (Commis |
|
| May 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? (Mark One) ? ?QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? ?TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-37359 ? BLUEPRINT MEDICINES CORPORATION (Exact Name of Registrant as Specified in Its Charter) ? Delaware 26-3632015 (State or Other Jurisdiction of Incorporation or Organization) (I. |
|
| May 3, 2022 |
EX-10.1 2 bpmc-20220331xex10d1.htm EX-10.1 Exhibit 10.1 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. EXECUTION VERSION COLLABORATION AND LICENSE AGREEMENT This Collaboration and License Agreement (this “Agreement”) is made and entered into as of February 26, 2022 (the |
|
| May 3, 2022 |
EX-10.2 3 bpmc-20220331xex10d2.htm EX-10.2 Exhibit 10.2 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. TENTH AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT This Tenth Amendment (this “Tenth Amendment”), effective April 30 2022 (“Tenth Amendment Effective Date”), is by |
|
| May 3, 2022 |
EX-99.1 2 tm2213933d2ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Blueprint Medicines Reports First Quarter 2022 Results - Achieved $23.8 million in AYVAKIT® (avapritinib) net product revenues, and $62.7 million in total revenues - - AYVAKYT® (avapritinib) launch in Germany underway following European Commission approval for advanced SM on March 25 – - First patients dosed in BLU-701, BLU-451, and BLU-222 |
|
| April 29, 2022 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? ? Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? ? ? Preliminary Proxy Statement ? ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 29, 2022 |
The registrant’s definitive proxy statement on Schedule 14A filed on April 29, 2022; UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: ? ? ? ? Preliminary Proxy Statement ? ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2 |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 26, 2022 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) (Com |
|
| April 8, 2022 |
EX-99.2 3 tm2212230d1ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Blueprint Medicines Announces BLU-945 Proof-of-Concept Data Supporting Initiation of Comprehensive Combination Development Strategy in EGFR-mutant Non-Small Cell Lung Cancer - Early dose escalation data show dose-dependent reductions in ctDNA and tumor burden - - Generally well-tolerated with most AEs Grade 1 or 2, supporting continued dose |
|
| April 8, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 8, 2022 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) (Comm |
|
| April 8, 2022 |
Precision that Moves Diane L. Patient with EGFR - driven lung cancer Exhibit 99.1 Precision that Moves Diane L. Patient with EGFR - driven lung cancer Blueprint Medicines call participants 2 Introduction and portfolio overview Kate Haviland Chief Executive Officer Initial data from the SYMPHONY trial of BLU - 945 presented at the AACR Annual Meeting 2022 David Spigel, M.D. Chief Scientific Officer Sarah Cannon Research Institute Portfolio strategy and next steps Fo |
|
| February 28, 2022 |
Exhibit 99.1 Blueprint Medicines and Proteovant Therapeutics Announce Strategic Collaboration to Advance Novel Targeted Protein Degrader Therapies - Collaboration will leverage Proteovant?s Artificial Intelligence-enhanced targeted protein degradation platform and Blueprint Medicines? small molecule precision medicine capabilities to address medical needs in oncology and hematology ? - Under the a |
|
| February 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 26, 2022 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) ( |
|
| February 17, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ? ? ? ? ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? ? ? ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to Commission File Number: 001-37359 BLUEPRINT MEDICINES CORPORATION (Exact name of registrant as specified in its charter) Delaware ? 26-3632015 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No. |
|
| February 17, 2022 |
UP TO $300,000,000 COMMON STOCK TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(5)? ?Registration Statement No.: 333-236424? PROSPECTUS SUPPLEMENT to Prospectus dated February 13, 2020 ? UP TO $300,000,000 COMMON STOCK We have entered into a Sales Agreement with Cowen and Company, LLC, or Cowen, relating to shares of our common stock, par value $0.001 per share, offered by this prospectus supplement and the accompanying prospec |
|
| February 17, 2022 |
Exhibit 10.54 ? CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL ? Confidential Execution Version ? ? ? ? ? ? LICENSE AND COLLABORATION AGREEMENT ? by and between ? ? Blueprint Medicines Corporation ? ? and ? ? Zai Lab (Shanghai) Co., Ltd ? ? |
|
| February 17, 2022 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Blueprint Medicines Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity 2015 Stock O |
|
| February 17, 2022 |
As filed with the Securities and Exchange Commission on February 17, 2022 As filed with the Securities and Exchange Commission on February 17, 2022 Registration No. |
|
| February 17, 2022 |
Exhibit 1.1 Execution Version BLUEPRINT MEDICINES CORPORATION $300,000,000 COMMON STOCK ? SALES AGREEMENT ? February 17, 2022 ? Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 ? Ladies and Gentlemen: ? Blueprint Medicines Corporation, a Delaware Corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1. Issuance and S |
|
| February 17, 2022 |
EX-FILING FEES 2 tm226132d1ex107.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table 424(b)(5) (Form Type) Blueprint Medicines Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum |
|
| February 17, 2022 |
EX-10.8 4 bpmc-20211231xex10d8.htm EX-10.8 Exhibit 10.8 THIRD AMENDMENT TO LEASE THIS THIRD AMENDMENT TO LEASE (this “Amendment”) is entered into as of this 15th day of December, 2021, by and between BRE-BMR 38 SIDNEY LLC, a Delaware limited liability company (“Landlord,” as successor-in-interest to Thirty-Eight Sidney Street LLC, which was successor-in-interest to Thirty-Eight Sidney Street Limit |
|
| February 17, 2022 |
Subsidiaries of the Registrant Exhibit 21.1 ? Subsidiaries of the Registrant ? ? ? Entity ? State/Jurisdiction of Incorporation or Organization Blueprint Medicines Security Corporation ? Massachusetts Blueprint Medicines (Switzerland) GmbH ? Switzerland Blueprint Medicines (Netherlands) B.V. ? Netherlands Blueprint Medicines (UK) Ltd. ? United Kingdom Blueprint Medicines (Germany) GmbH ? Germany Blueprint Medicines Spain, S.L. |
|
| February 16, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 16, 2022 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) ( |
|
| February 16, 2022 |
Exhibit 99.1 Blueprint Medicines Reports Fourth Quarter and Full Year 2021 Results - Achieved $53.0 million in AYVAKIT net product revenues and $180.1 million in total revenues in 2021 - - Anticipate approximately $115 million to $130 million in AYVAKIT net product revenues and $180 million to $200 million in total revenues in 2022 - - Multiple abstracts accepted for presentation at the AACR annua |
|
| February 9, 2022 |
BPMC / Blueprint Medicines Corp / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Blueprint Medicines Corp. Title of Class of Securities: Common Stock CUSIP Number: 09627Y109 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is fi |
|
| February 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Blueprint Medicines Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 09627Y109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| January 20, 2022 |
Exhibit 99.1 Blueprint Medicines Elevates Two Talented Leaders to its Executive Team - Philina Lee, Ph.D., promoted to Chief Commercial Officer - - Helen Ho, Ph.D., role expanded to Chief Business Officer – - Demonstrates strong bench of talent and commitment to diversity in roles of all levels within Blueprint Medicines - CAMBRIDGE, Mass., (Jan. 20, 2022) / PRNewswire/ - Blueprint Medicines Corpo |
|
| January 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 19, 2022 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) (C |
|
| January 20, 2022 |
Exhibit 10.1 EXECUTION COPY AMENDED & RESTATED EMPLOYMENT AGREEMENT This Amended & Restated Employment Agreement (?Agreement?) is between Blueprint Medicines Corporation, a Delaware corporation (the ?Company?), and Philina Lee (the ?Executive?) and is effective as of April 4, 2022 (the ?Effective Date?). WHEREAS, the Company and the Executive are parties to the Employment Agreement dated as of Jan |
|
| January 10, 2022 |
Exhibit 99.2 Blueprint Medicines Provides 2022 Portfolio Goals Targeting Expanded Precision Therapy Leadership ? Achieved full-year 2021 preliminary global net product revenue for AYVAKIT of approximately $52.9 million, representing an increase of approximately 150% over 2020 based on strong initial U.S. demand in advanced SM ? ? Registration-enabling PIONEER trial of AYVAKIT in non-advanced syste |
|
| January 10, 2022 |
Pioneering the Science of Time Cyndi N. Systemic mastocytosis patient Exhibit 99.1 Pioneering the Science of Time Cyndi N. Systemic mastocytosis patient Forward - looking statements 2 This presentation contains forward - looking statements as defined in the Private Securities Litigation Reform Act of 1995 , as amended . The words "aim," "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," " |
|
| January 10, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 10, 2022 Blueprint Medicines Corporation (Exact name of registrant as specified in its charter) Delaware 001-37359 26-3632015 (State or other jurisdiction of incorporation) (C |
|
| January 5, 2022 |
Exhibit 10.3 EXECUTION COPY AMENDED & RESTATED EMPLOYMENT AGREEMENT This Amended & Restated Employment Agreement (?Agreement?) is between Blueprint Medicines Corporation, a Delaware corporation (the ?Company?), and Christina Rossi (the ?Executive?) and is effective as of April 4, 2022 (the ?Effective Date?). WHEREAS, the Company and the Executive are parties to the Employment Agreement dated as of |
